ArticleFrontiers in endocrinology2026
Guiding immunotherapy based on the oxford classification activity score in IgA nephropathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of Oxford classification in guiding immunotherapy management strategies remains a subject of debate. Our study aimed to explore different combinations of Oxford Classification activity scores in guiding immunotherapy for IgA nephropathy. Objective: We introduced a sum scores to analyze composite pathological score association with immunotherapy for proteinuria remission, aiming to further elucidate the clinical utility of renal histology in immunotherapy decisions. Methods: A total of 3,196 patients were diagnosed with IgA nephropathy, as confirmed by renal biopsy, between May 2018 and November 2023. However, only 2,389 patients were enrolled after the exclusion criteria were applied. The cohort included 1,211 patients receiving immunosuppressive therapy and 1,178 patients managed with supportive care. Patients with complete outcomes were selected, and the characteristics between groups were balanced using propensity score matching. We subsequently employed both Kaplan-Meier and Cox regression analyses to investigate the impact of immunotherapy on proteinuria remission. We defined SumMEC (the sum of the M, E, and C scores) as a potential immunotherapy responsiveness score. Furthermore, we conducted a subgroup analysis to explore the association between different SumMEC subgroups and the effect of immunotherapy. Results: A multivariate Cox regression analysis revealed that immunotherapy was associated with a 22% increase in proteinuria remission at 12 months in patients with IgAN (HR 1.22; 95% CI 1.07-1.40; p=0.004). Subgroup analyses demonstrated this benefit only in patients with high SumMEC scores. The effects of immunotherapy and the SumMEC score on 6-month proteinuria remission are comparable to those observed at 12 months. Conclusions: The use of immunosuppressive agents may improve proteinuria remission in patients with IgA nephropathy. Patients with high SumMEC scores responded positively to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.